Volume 4, Issue 6: THE HCV VIRAL LIFE CYCLE AND TREATMENT IN HIV COINFECTION AND DIALYSIS POPULATIONS
e-Viral Hepatitis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Hepatitis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 4, Issue 6)
Target Audience
Nurses and health care professionals involved in the care of patients with Hepatitis.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
- Describe the HCV life cycle, drug targets, and interactions between HIV-HCV viruses in coinfection.
- Evaluate the data on sofosbuvir/ledipasvir, sofosbuvir/daclatasvir, paritaprevir/ritonavir/ombitasvir and dasabuvir (3D) and grazoprevir/elbasvir for the treatment of HCV in HIV-HCV coinfected patients.
- Summarize the current evidence providing guidance on HCV treatment options in ESRD patients who need to be treated urgently.
Paul Martin, MD, FRCP, FRCPI
Professor of Medicine, Chief Division of Hepatology
University of Miami School of Medicine
Miami, Florida
Kalyan Ram Bhamidimarri, MD, MPH
Assistant Professor of Clinical Medicine
Medical Director for Small Bowel & Multi-Visceral Transplantation
University of Miami School of Medicine
Miami Transplant Institute
Miami, Florida
Available Credit
- 1.00 ANCC
- 1.00 Attendance